Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 10/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008356 | 0.87 | YTHDC1 (0.53) | PRKAG1PRKAA1PRKAB1NTRK1CSNK2A1 | |
| SCHEMBL4009831 | 0.84 | CSNK2A1 (0.54) | PRKAA1CSNK2A1ROCK1CDK2FLT3 | |
| SCHEMBL4006912 | 0.83 | MEN1 (0.41) | TTKMAPK8F2NTRK1CSNK2A1 | |
| SCHEMBL4004255 | 0.82 | CYP1A2 (0.39) | TTKMAPK8F2 | |
| SCHEMBL4007967 | 0.81 | NTRK1 (0.41) | PRKAA1NTRK1CSNK2A1KDM4ESTAT3 | |
| SCHEMBL4007104 | 0.81 | F2 (0.38) | TTKMAPK8F2 | |
| SCHEMBL4003706 | 0.81 | TTK (0.37) | TTKMAPK8F2NTRK1CSNK2A1 | |
| SCHEMBL4007930 | 0.80 | TTK (0.56) | TTKMAPK8NTRK1CSNK2A1KDM4E | |
| SCHEMBL6554266 | 0.79 | CSNK2A1 (0.45) | PRKAA1NTRK1CSNK2A1ROCK1CDK2 | |
| SCHEMBL6554271 | 0.79 | CSNK2A1 (0.45) | PRKAA1NTRK1CSNK2A1ROCK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PRKAG1 333/4885PRKAA1 137/4885PRKAB1 417/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PRKAG1 271/4885PRKAA1 122/4885PRKAB1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.